Participation of Women in Cardiovascular Trials From 2017 to 2023

作者：Frederick Berro Rivera, John Vincent Magalong, Nathan Ross B. Bantayan, Nicole Ann Tesoro, Mark Jason Milan, Vikramjit Purewal, Polyn Luz S Pine, Chieh-Mei Tsai, Ann Marie Návar, Sharon L. Mulvagh, James L. Januzzi, C. Michael Gibson, Anuradha Lala-Trindade, Susan Cheng, Kyla Lara-Breitinger, Mayra Guerrero, Martha Gulati · 发表于：JAMA Network Open · 年份：2025 · DOI：10.1001/jamanetworkopen.2025.29104 · 被引用次数：34 · 研究领域：Sex and Gender in Healthcare、Acute Myocardial Infarction Research、Diversity and Career in Medicine

Importance: Cardiovascular (CV) disease is the leading cause of death globally for both men and women, yet women remain historically underrepresented in CV clinical trials, despite facing a disproportionately high burden of morbidity and mortality in many forms of CV disease. Objective: To determine the representation of women across a broad range of CV trials. Evidence Review: The participation of women in CV trials registered on ClinicalTrials.gov from 2017 to 2023 was systematically determined through the extraction of publicly available information. Data were extracted to identify the country of study, disease type, trial size, clinical intervention, and age of the participants. The proportion of women and the ratio of number of female to male participants (F:M ratio) were calculated for each trial. The women's participation:prevalence ratio (PPR) was estimated for each trial based on the relative prevalence of the disease by sex in the specified region. Findings: A total of 1079 registered CV trials were identified, including 1 396 104 participants, of whom 571 641 (41.0%) were women. The F:M ratio was significantly lower for studies on arrhythmia (median [IQR], 0.5), coronary heart disease (median [IQR], 0.39 [0.33-0.70]), acute coronary syndrome (median [IQR], 0.32 [0.24-0.51]), and heart failure (median [IQR], 0.51 [0.32-0.87]) but higher for obesity (median [IQR], 1.44 [1.08-4.50]) and pulmonary hypertension (median [IQR], 2.86 [1.50-3.97]) trials. The F:M ratio was ...